Cyclooxygenase (COX) Inhibitors and the Newborn Kidney

Pharmaceuticals

Francine G. Smith¹  Andrew W. Wade²  Megan L. Lewis¹ 

[1] Department of Physiology and Pharmacology, University of Calgary, Alberta, T2N 4N1, Canada;Alberta Children’s Hospital Research Institute for Child and Maternal Health, University of Calgary, Alberta, T2N 4N1, Canada

关键词: perinatal;    prostaglandins;    newborn;    patent ductus arteriosis;    premature labour;    indomethacin;    COX-1;    COX-2;    neonate;    COX inhibitors;   

DOI  :  10.3390/ph5111160

来源: mdpi

【 摘 要 】

This review summarizes our current understanding of the role of cyclo-oxygenase inhibitors (COXI) in influencing the structural development as well as the function of the developing kidney. COXI administered either during pregnancy or after birth can influence kidney development including nephronogenesis, and can decrease renal perfusion and ultrafiltration potentially leading to acute kidney injury in the newborn period. To date, which COX isoform (COX-1 or COX-2) plays a more important role in during fetal development and influences kidney function early in life is not known, though evidence points to a predominant role for COX-2. Clinical implications of the use of COXI in pregnancy and in the newborn infant are also evaluated herein, with specific reference to the potential effects of COXI on nephronogenesis as well as newborn kidney function.

【 授权许可】

CC BY   
© 2012 by the authors; licensee MDPI, Basel, Switzerland.